Canaccord analyst Edward Nash raised the firm’s price target on Intercept to $20 from $18 and keeps a Buy rating on the shares. The firm said given the significant cost-cutting measures and continued growth in Ocaliva, the company seems well on its way to achieving profitability.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ICPT:
- Intercept raises FY23 Ocaliva net sales view to $320M-$340M from $310M-$340M
- Intercept reports Q2 EPS (14c), consensus (51c)
- Intercept Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Oppenheimer biotechnology analyst to hold an analyst/industry conference call
- Meta upgraded, Coinbase downgraded: Wall Street’s top analyst calls
